Figure 3.

CD40 mutants that retain TRAF2 binding are capable of signaling through the NF-κB and SAPK/JNK1 pathways upon activation. Twenty-five million BI141 cells were either untreated or treated with 1 μg/ml of the murine anti-human CD40 mAb, G28.5, for 30 min, at which point the samples were either processed for NF-κB-dependent gel-shift assays or for the SAPK-dependent phosphorylation of GST-Jun.